Synlogic announces closing of $21.0 million underwritten public offering

Cambridge, mass., oct. 03, 2023 (globe newswire) -- synlogic, inc. (nasdaq: sybx), a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to transform the care of serious diseases, today announced the closing of its previously announced underwritten public offering.

SYBX Ratings Summary

SYBX Quant Ranking